Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia.
Public health
Virus diseases
Journal
The Medical journal of Australia
ISSN: 1326-5377
Titre abrégé: Med J Aust
Pays: Australia
ID NLM: 0400714
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
25
02
2020
accepted:
05
03
2020
pubmed:
3
4
2020
medline:
13
6
2020
entrez:
3
4
2020
Statut:
ppublish
Résumé
To describe the first isolation and sequencing of SARS-CoV-2 in Australia and rapid sharing of the isolate. SARS-CoV-2 was isolated from a 58-year-old man from Wuhan, China who arrived in Melbourne on 19 January 2020 and was admitted to the Monash Medical Centre, Melbourne from the emergency department on 24 January 2020 with fever, cough, and progressive dyspnoea. Clinical course and laboratory features of the first reported case of COVID-19 (the illness caused by SARS-CoV-2) in Australia; isolation, whole genome sequencing, imaging, and rapid sharing of virus from the patient. A nasopharyngeal swab and sputum collected when the patient presented to hospital were each positive for SARS-CoV-2 (reverse transcription polymerase chain reaction). Inoculation of Vero/hSLAM cells with material from the nasopharyngeal swab led to the isolation of SARS-CoV-2 virus in culture. Electron microscopy of the supernatant confirmed the presence of virus particles with morphology characteristic of viruses of the family Coronaviridae. Whole genome sequencing of the viral isolate and phylogenetic analysis indicated the isolate exhibited greater than 99.99% sequence identity with other publicly available SARS-CoV-2 genomes. Within 24 hours of isolation, the first Australian SARS-CoV-2 isolate was shared with local and overseas reference laboratories and major North American and European culture collections. The ability to rapidly identify, propagate, and internationally share our SARS-CoV-2 isolate is an important step in collaborative scientific efforts to deal effectively with this international public health emergency by developing better diagnostic procedures, vaccine candidates, and antiviral agents.
Identifiants
pubmed: 32237278
doi: 10.5694/mja2.50569
pmc: PMC7228321
doi:
Banques de données
GENBANK
['NC_045512.3', 'MT007544.1', 'EPI_ISL_406844']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
459-462Subventions
Organisme : NHMRC
Pays : International
Organisme : Victorian Department of Health and Human Services
Pays : International
Organisme : University of Wisconsin Medical Foundation
Pays : International
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 AMPCo Pty Ltd.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Clin Microbiol. 2019 Dec 23;58(1):
pubmed: 31666364
Euro Surveill. 2018 Dec;23(50):
pubmed: 30563591
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
J Virol. 2011 Dec;85(23):12815-20
pubmed: 21957308
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079